



Hemogenyx Pharma Plc - Investor presentation

6/8/2018

RNS Number : 6849Q

Hemogenyx Pharmaceuticals PLC

08 June 2018

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Investor presentation

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it will hold a presentation for investors on Tuesday 26th June 2018.

The briefing by Dr. Vladislav Sandler, CEO of Hemogenyx, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com

Enquiries:

Hemogenyx Pharmaceuticals Limited

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Sir Marc Feldmann, Chairman

www.hemogenyx.com

Via Walbrook PR

Optiva Securities Ltd

Christian Dennis

Tel: +44 (0)20 3137 1902

Shard Capital Partners LLP

Damon Heath, Erik Woolgar

Tel: +44 (0)20 7186 9950

Peterhouse Corporate Finance Limited

Lucy Williams/Duncan Vasey

Tel: +44 (0)20 7469 0930

Walbrook PR

Paul McManus

Tel: +44 (0)20 7933 8780 or **hemogenyx@walbrookpr.com**

Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit **www.hemogenyx.com**.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact **rns@lseg.com** or visit **www.rns.com**.

END

NRAUBVURWWANRAR

